spacer
home > ebr > autumn 2018 > candidate selection
PUBLICATIONS
European Biopharmaceutical Review

Candidate Selection

In recent years, significant advancement has been made in the clinical application of cancer immunotherapies. Molecules directed against immune checkpoints and other agonists show great promise for treatment of a variety of malignancies. In addition to CTLA-4 and PD-1 blockade, a wide range of therapeutics with the potential to reverse the tumour-induced suppression are under development. Despite the first successes, only a relatively small portion of patients benefit from these treatments, and it has been shown that combination therapies can improve the outcome. Today, over a thousand trials of immune checkpoints are running, resulting in some critical questions, such as:

• Are combinations being tested too quickly and that might never work
• Is the workload being doubled and efforts and chances of patients to participate in the most promising trials being wasted

Early evaluation of the effectiveness of candidate therapeutics and combination therapies can be done using mouse models and in vitro bioassays with primary mouse or human immune cells. Also, a better understanding of the tumour microenvironment and the steps needed to generate an anti-tumour response by the immune system will help design clinical trials and, ultimately, discover relevant biomarkers. Finally, dealing with the potential unwanted immunogenicity of oncology drugs is important, as the development of anti-drug antibodies (ADA) might lead to an altered efficacy and potency and autoimmune responses.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thibault Janss holds a master’s degree in biochemistry, molecular, and cellular biology from the University of Liège, Belgium. Thibault received his PhD at the Grappe Interdisciplinaire de Génoprotéomique Appliquée in Liège, where he acquired a strong experience in the immunology field, working on dendritic cells and T-cell interactions. During this period, Thibault also developed an in-depth knowledge of flow cytometry. He joined ImmunXperts as a Senior Scientist at the beginning of 2017.

Sofie Pattijn is the Chief Technology Officer and Founder at ImmunXperts, and has over 20 years of experience in the field of immunogenicity assessment and in vitro assay development. Sofie has extensive hands-on lab experience and has managed and coached several in vitro teams over the last decade. From 2008 until 2013, she was Head of the in vitro immunogenicity group at AlgoNomics and Lonza Applied Protein Services. Prior to that, Sofie worked at Innogenetics for over 15 years.
spacer
Thibault Janss
spacer
spacer
spacer
Sofie Pattijn
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Continues Commitment to Oncology Drug Discovery

Charles River Laboratories International, Inc. (NYSE: CRL) today announced new additions to the Tumor Model Compendium. Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research.
More info >>

White Papers

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

RSSL

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >>

 
Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement